SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma.
Asthma, a chronic inflammatory fluctuating disease with day-to-day variability in lung function and symptoms, is estimated to affect 339 million individuals worldwide [1]. The long-term goals of asthma management are to achieve good control of asthma symptoms and to minimise the risk of asthma-related death, exacerbations, and persistent airflow limitation [2]. As such, treatment with inhaled corticosteroids (ICS) to control the underlying airway inflammation is the cornerstone of asthma management. However, previous global treatment recommendations and several current national treatment guidelines recommend short-acting β2-agonists (SABAs) for use as-needed for symptom relief across all asthma severities, and as monotherapy treatment for the mildest form of asthma [3, 4].